265 related articles for article (PubMed ID: 12955673)
1. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
Tuttle KR; Anderson PW
Am J Kidney Dis; 2003 Sep; 42(3):456-65. PubMed ID: 12955673
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.
Kelly DJ; Zhang Y; Hepper C; Gow RM; Jaworski K; Kemp BE; Wilkinson-Berka JL; Gilbert RE
Diabetes; 2003 Feb; 52(2):512-8. PubMed ID: 12540629
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
Koya D; Haneda M; Nakagawa H; Isshiki K; Sato H; Maeda S; Sugimoto T; Yasuda H; Kashiwagi A; Ways DK; King GL; Kikkawa R
FASEB J; 2000 Mar; 14(3):439-47. PubMed ID: 10698958
[TBL] [Abstract][Full Text] [Related]
4. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy.
Anderson PW; McGill JB; Tuttle KR
Curr Opin Nephrol Hypertens; 2007 Sep; 16(5):397-402. PubMed ID: 17693752
[TBL] [Abstract][Full Text] [Related]
6. Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients?
He Z; King GL
Diabetes Care; 2005 Nov; 28(11):2803-5. PubMed ID: 16249561
[No Abstract] [Full Text] [Related]
7. Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice.
Meier M; Menne J; Haller H
Diabetologia; 2009 May; 52(5):765-75. PubMed ID: 19238353
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
Kelly DJ; Chanty A; Gow RM; Zhang Y; Gilbert RE
J Am Soc Nephrol; 2005 Jun; 16(6):1654-60. PubMed ID: 15843473
[TBL] [Abstract][Full Text] [Related]
9. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats.
Koya D; Jirousek MR; Lin YW; Ishii H; Kuboki K; King GL
J Clin Invest; 1997 Jul; 100(1):115-26. PubMed ID: 9202063
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C-beta inhibition for diabetic kidney disease.
Tuttle KR
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S70-4. PubMed ID: 18977550
[TBL] [Abstract][Full Text] [Related]
11. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes.
Cotter MA; Jack AM; Cameron NE
Clin Sci (Lond); 2002 Sep; 103(3):311-21. PubMed ID: 12193157
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy.
Connelly KA; Kelly DJ; Zhang Y; Prior DL; Advani A; Cox AJ; Thai K; Krum H; Gilbert RE
Circ Heart Fail; 2009 Mar; 2(2):129-37. PubMed ID: 19808328
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease.
Kelly DJ; Edgley AJ; Zhang Y; Thai K; Tan SM; Cox AJ; Advani A; Connelly KA; Whiteside CI; Gilbert RE
Nephrol Dial Transplant; 2009 Jun; 24(6):1782-90. PubMed ID: 19155535
[TBL] [Abstract][Full Text] [Related]
14. Ruboxistaurin.
Taulien CA; Joy SV
Drugs Today (Barc); 2006 Sep; 42(9):577-85. PubMed ID: 17028667
[TBL] [Abstract][Full Text] [Related]
15. PKC-B inhibition: a new therapeutic approach for diabetic complications?
Avignon A; Sultan A
Diabetes Metab; 2006 Jun; 32(3):205-13. PubMed ID: 16799396
[TBL] [Abstract][Full Text] [Related]
16. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
Kelly DJ; Buck D; Cox AJ; Zhang Y; Gilbert RE
Am J Physiol Renal Physiol; 2007 Aug; 293(2):F565-74. PubMed ID: 17522264
[TBL] [Abstract][Full Text] [Related]
17. The role of protein kinase C activation and the vascular complications of diabetes.
Das Evcimen N; King GL
Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy.
Menne J; Shushakova N; Bartels J; Kiyan Y; Laudeley R; Haller H; Park JK; Meier M
Diabetes; 2013 Apr; 62(4):1167-74. PubMed ID: 23434935
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor.
Ishii H; Jirousek MR; Koya D; Takagi C; Xia P; Clermont A; Bursell SE; Kern TS; Ballas LM; Heath WF; Stramm LE; Feener EP; King GL
Science; 1996 May; 272(5262):728-31. PubMed ID: 8614835
[TBL] [Abstract][Full Text] [Related]
20. Ruboxistaurin: LY 333531.
Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
